This study is exploring new treatment options for colorectal cancer that cannot be removed by surgery. The focus is on a special type of cancer with a gene change called KRAS G12C. Researchers want to see if adding calderasib and cetuximab to standard chemotherapy helps improve outcomes. They aim to find out if this combination is safe and if it helps people live longer without the cancer growing or spreading.
The trial ID is NCT06997497. This is a Phase 3 study, which means it is looking at how well the treatment works and its safety. The trial is FDA-regulated and aims to enroll about 477 participants.
Who can join
This trial is open to adults aged 18 and older, including both men and women. Participants must have a specific type of colorectal cancer with a confirmed KRAS G12C mutation. Some health conditions may prevent someone from joining, but the trial team will confirm eligibility during screening.
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly assigned to one of two treatment groups. One group will receive calderasib, cetuximab, and standard chemotherapy called mFOLFOX6. The other group will receive just mFOLFOX6, with some possibly getting bevacizumab. Treatments will continue until certain criteria are met.
Where
This trial is enrolling at 27 locations. Recruiting sites are listed first.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Directs genitourinary oncology at Huntsman Cancer Institute. Treats pancreatic cancer, liver cancer, gallbladder cancer and esophageal cancer. Also treats stomach cancer and colorectal cancer.
Treats colorectal cancer. Offers minimally invasive surgery, laparoscopic surgery and robotic surgery. A surgeon is the doctor who removes cancer with an operation (adults). Recognized at state, national or international level.